MV Chandrakanth, Academic Head and Medical Oncologist at Narayana Health, shared on X:

“TALAPRO-3 / 52% less progression – but at what cost?

NEJM 2026 / The Upfront vs Sequential PARP Debate

52% reduction in progression/death risk with talazoparib + enzalutamide + ADT (HR 0.48).
BRCA-altered subgroup: Particularly impressive rPFS benefit (HR 0.37).
Overall survival: Immature; no established OS benefit yet (HR 0.77).
Toxicity matters: Grade ≥3 anemia 51%, RBC transfusions 40%, permanent talazoparib discontinuation 19%.
The sequencing controversy: Only 10% of control patients subsequently received PARP inhibition.
The unanswered question: Is upfront PARP inhibition truly superior to optimal sequencing? TALAPRO-3 did not directly compare these strategies.

Reference: TALAPRO-3 Correspondence. NEJM, November 2026.”

Title: PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer

Authors: Neeraj Agarwal, Nobuaki Matsubara, Arun A Azad, Fred Saad, Joaquin Mateo, Shusuan Jiang, Dingwei Ye, Eric Voog, Neal D Shore, Timuçin Çil, Christof Vulsteke, Hsiao-Jen Chung, Stefanie Zschäbitz, A Douglas Laird, Xiaoxi Zhang, Prachi Nandoskar, Sarah Fenech Chetcuti, Fong Wang, Karim Fizazi

Read the full article.

You can also read:

TALAPRO-3 at ESMO 2026: Prognostic Utility of ctDNA Tumour Fraction in mCSPC